^
Association details:
| Biomarker: | STK11 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Excerpt:
Objective response rates to PD-1 blockade differed significantly among KL (7.4%), KP (35.7%), and K-only (28.6%) subgroups (P < 0.001) in the Stand Up To Cancer (SU2C) cohort (174 patients) with KRAS-mutant LUAC and in patients treated with nivolumab in the CheckMate-057 phase III trial (0% vs. 57.1% vs. 18.2%; P = 0.047). In the SU2C cohort, KL LUAC exhibited shorter progression-free (P < 0.001) and overall (P = 0.0015) survival compared with KRASMUT;STK11/LKB1WT LUAC.
DOI:
10.1158/2159-8290.CD-18-0099
Trial ID:
Source:
Title:
Association of STK11/LKB1 mutations with primary resistance to PD-1/PD-L1 axis blockade in PD-L1 positive non-squamous NSCLC.
Excerpt:
66 patients with non-squamous NSCLC treated with PD-1/PD-L1 inhibitors at MDACC (61% pembrolizumab, 24% nivolumab, 8% atezolizumab, 5% durvalumab/tremelimumab) with available STK11/LKB1 NGS-based genomic profiling and positive tumor cell PD-L1 expression...STK11/LKB1 genomic alterations are associated with de novo resistance to PD-1/PD-L1 inhibitors even among PD-L1-positive non-squamous NSCLC patients, suggesting that their effect is at least partially independent of PD-L1 expression.
DOI:
10.1200/JCO.2018.36.15_suppl.9028
